CANCER MONOCLONAL ANTIBODIES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Key Takeaways from Analyst

The rising prevalence of various cancer types globally is a major driver for increasing demand of monoclonal antibodies-based drugs.

North America will continue dominating due to established research capacities and faster uptake of premium-priced drugs among patients and healthcare providers. Major pharmaceutical firms are also boosting regional manufacturing scale to improve access. Asia Pacific is likely to emerge as the fastest growing regional market due to rapid economic development, growing healthcare spending, and increasing focus on cancer care infrastructure across China, India, South Korea, and other countries that provide an appealing growth environment.

High development costs of monoclonal antibodies and subsequent pricing pressures pose significant challenges. Manufacturers will need to balance investments in research with financial returns to sustain long-term growth. Biosimilars emergence also increases treatment affordability but cannibalizes originator drugs sales.